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Abstract
Background: Patients with acute mesenteric ischemia (AMI) often exhibit severe co-morbidities and significant surgical
risks, leading to high perioperative morbidity.
Purpose: To investigate the feasibility of primary percutaneous stent-revascularization (PPSR) in atherosclerotic AMI
and its impact on patients’ outcome.
Material and Methods: Retrospective analysis of 19 consecutive patients (7 women, 12 men; median age, 69 years)
with AMI caused by atherosclerotic, non-embolic stenoses/occlusions of the splanchnic arteries and PPSR. Alternative
minimally invasive techniques were excluded. Clinical characteristics including the Charlson Comorbidity Index adjusted
by age (CCIa) and symptom duration, technical and clinical success of PPSR, clinical course, 30-day mortality, and follow-
up were evaluated and compared to literature data for surgical approaches. Technical success was defined as residual
stenosis of <30% in diameter. Clinical success was defined as resolution of symptoms of AMI and/or normalization of
serum lactate after sole PPSR.
Results: The majority of patients presented with severe co-morbidities (CCIa >4 in 17 of 19 patients, 89%). Median
symptom duration was 50 h. Technical and clinical success rates of PPSR were 95% (21 of 22 arteries) and 53% (10 of 19
patients). Seven patients underwent subsequent laparotomy with bowel resection in four cases. Thirty-day mortality was
42% (8 of 19 patients).
Conclusion: In our study population of patients with atherosclerotic AMI, severe co-morbidities, prolonged acute
symptoms, and significant perioperative risks PPSR of splanchnic stenoses were technically feasible and the clinical
outcome was acceptable.
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Introduction
Stenosis of the splanchnic arteries (celiac trunk, super-
ior mesenteric artery [SMA] and inferior mesenteric
artery [IMA]) is commonly the consequence of athero-
sclerosis (1–3). Progressive disease may lead to insuffi-
cient bowel perfusion and symptoms of chronic
mesenteric ischemia (CMI) can emerge (2,4,5). In
these patients, primary percutaneous stent-revasculari-
zation (PPSR) represents an already well established
therapy option with high technical and clinical success
rates (6,7).
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Due to further vessel narrowing and/or periods of
arterial hypotension, symptoms of acute mesenteric
ischemia (AMI) may occur (1,2,5). In case of persistent
insufficient bowel perfusion, reversible bowel ischemia
progresses to irreversible necrosis (8). The standard ther-
apy of AMI is surgical revascularization of splanchnic
arteries by means of arterial bypass grafting or throm-
boembolectomy and resection of necrotic bowel seg-
ments (2,8,9). This approach requires laparotomy and
may be challenging in patients with severe atheroscler-
osis, prior abdominal surgery, peritonitis, and/or signifi-
cant co-morbidities (1,2,9–12). To overcome the surgical
risks and morbidity, minimally invasive, endovascular
approaches including intraoperative retrograde stenting
of the SMA as well as percutaneous revascularization
are increasingly performed (1,2,5,13–21).
The purpose of this study was to investigate the
feasibility of PPSR in patients with AMI, caused by
atherosclerotic stenoses/occlusions (but not embolic
occlusions) of the splanchnic arteries, and its impact
on the clinical outcome.
Material and Methods
Data collection
At the University Medical Center Regensburg, a total of
19 consecutive patients (7women, 12men;median age, 69
years; age range, 50–88 years)withAMIunderwent PPSR
of atherosclerotic stenoses of the splanchnic arteries
between January 1999andFebruary 2011.Embolic occlu-
sions – representinganother commoncauseofAMIwhere
the embolus is usually located at least 3 cm distal from the
ostium–were not included in this survey.Alternativemin-
imally invasive approaches (e.g. transluminal aspiration
(13)) and primary laparotomy were excluded as well.
We retrospectively analyzed the patients’ medical rec-
ords and imaging data focusing on clinical characteristics
including the extent of co-morbidities and time interval
between onset of acute symptoms and PPSR, the tech-
nical and clinical success of PPSR, the clinical course
including need of subsequent laparotomy and bowel
resection, and 30-day mortality as well as follow-up.
An institutional review board approval was not
required for publishing a retrospective study. The prin-
ciples of the Declaration of Helsinki were followed. All
patients and/or their relatives gave informed consent
prior to inclusion in this study.
Definition of AMI
AMI was present if: (i) the patients showed typical signs
and symptoms of AMI (persistent abdominal pain,
gastrointestinal bleeding, clinical peritonitis, pneumatosis
intestinalis, portal venous gas, shock, and/or elevated
serum lactate); (ii) at least one splanchnic artery showed
a stenosis of >50% in diameter; and (iii) there was no
other disease that accounted for the symptoms (6).
Co-morbidities
The Charlson Comorbidity Index adjusted by age
(CCIa) (22) was used in order to compare the survival
with current literature data of primary open surgical
approach considering the extent of co-morbidities and
the patients’ age.
Laboratory, imaging, and interventional data
The serum values of C-reactive protein (CRP), white
blood cell (WBC) count, and lactate temporally nearest
to PPSR were documented.
Contrast-enhanced arterial and portal venous phase
computed tomography (CT) scans of the abdomen and
pelvis were acquired. CT images were reconstructed in
the axial and coronal planes (3-mm slice width/3-mm
intervals). Diagnostic digital subtraction angiography
(DSA) started with an anterior-posterior abdominal
aortography in order to visualize the flow dynamics
and potential collateral perfusion of the splanchnic
arteries. Subsequently, selective lateral images of the
stenotic splanchnic arteries were carried out.
CT and DSA data were read in consensus by two
radiologists with 5 (FR) and 12 (HP) years of experi-
ence in body imaging. Based on visual grading of the
splanchnic arteries, a stenosis of 51–70% and 71–99%
in diameter was defined as moderate and high-grade
stenosis, respectively. Thickness of the bowel wall of
>3mm was considered pathologic (23) and signs of
AMI (non-enhancing bowel wall, pneumatosis intesti-
nalis, portal venous gas, free intraperitoneal air)
were documented. Furthermore, findings of endoscopy
were supplemented. Concerning interventional data
analysis, the duration of PPSR, the kind and size of
implanted stents, technical and clinical success as well
as peri-interventional complications were assessed.
Technical success (based on intention-to-treat) was
defined as successful completion of the intervention
and a residual stenosis of <30% in diameter (5,17).
Clinical success was defined as resolution of symptoms
of AMI and/or normalization of serum lactate after
sole PPSR.
Decision-making process
Each case was discussed interdisciplinary by a general
surgeon, a vascular surgeon, and an interventional radi-
ologist. In detail, the pros and cons of primary surgical
revascularization and PPSR were evaluated, taking into
account the patients’ general condition, co-morbidities,
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and other surgical risk factors such as severe splanchnic
calcifications and prior laparotomies with potential
abdominal adhesions. In each case, the physicians and
the patient and/or their relatives decided in consensus
to attempt PPSR. Subsequent laparotomy was indi-
cated if signs or symptoms of AMI persisted, recurred,
or got worse.
Endovascular technique
In four (21%) and 15 of 19 patients (79%) a brachial
and femoral access, respectively, was chosen. If the SMA
was stenotic or occluded, the primary aim was to revas-
cularize this artery. If an occluded SMA could not be
revascularized and a stenosis of the celiac trunk and/or
the IMA was identified, it was attempted to revascular-
ize primarily the celiac trunk and alternatively the IMA
in order to improve perfusion of the small bowel via
arterial collaterals (e.g. via pancreatic arcades). Prior
to selective catheterization of the splanchnic arteries,
2500 or 5000 units of heparin were administered,
dependent on the interventionist’s preference and his-
tory of recent gastrointestinal bleeding. Then, the tip
of a 5–7 French sheath was carefully advanced through
the stenosis. In case of severe or circular calcification,
the stenosis was dilated with, for example, a 3mm bal-
loon prior to sheath advancement. The interventionist
inserted a stent of his preference considering the diam-
eter of the treated artery. If completion angiography
depicted a residual stenosis of >30%, balloon angio-
plasty was performed or a second stent was implanted.
To prevent acute in-stent thrombosis prior to stent
release, 100mg or 250mg acetylsalicylic acid were
administered according to the interventionists’ prefer-
ence considering recent gastrointestinal bleeding. To
prevent in-stent neointimal hyperplasia platelet aggrega-
tion inhibition was continued with 100mg acetylsalicylic
acid per day lifelong. As soon as the patient was in a
stable condition without need of additional operative
treatment, 75mg clopidogrel per day for at least 6
weeks were administered.
Results
Details of the 19 patients with PPSR are summarized in
Supplementary Table 1 (available online).
Co-morbidities
Each of the 19 patients exhibited at least one co-mor-
bidity (median, 3; range, 1–7). The median CCIa score
was 6 (range, 3–17). Moderate to severe renal disease
(12 of 19 patients, 63%) and peripheral vascular disease
(10 of 19 patients, 53%) were the most prevalent co-
morbidities.
Abdominal symptoms, laboratory parameters,
and imaging findings
Three patients were not responsive and/or anesthetized
(patients 5, 6, and 18). Twelve of the remaining 16
patients (75%) reported persistent abdominal pain.
Two of 19 patients (11%) exhibited clinical peritonitis
(patients 6 and 7) and seven of 19 patients (37%) suf-
fered from gastrointestinal bleeding. Median time inter-
val between onset of symptoms of AMI and/or
elevation of lactate and PPSR was 50 h (range, 8 h–12
days). Five patients reported history of CMI (patients
2, 8, 9, 12, and 16).
Median levels of CRP, WBC count, and lactate were
124mg/L (range, 9–301mg/L), 13/nL (range, 6–32/nL),
and 20mg/dL (range, 10–68mg/dL), respectively. The
levels of CRP, WBC count, and lactate were increased
above normal in 14 of 14 (100%), 11 of 17 (65%) and
six of 12 patients (50%) with available laboratory data,
respectively.
CT showed pneumatosis intestinalis in three cases
(patients 6, 7, and 14) including gas within the portal
veins in one participant (patient 14). The bowel wall
was pathological thickened in nine patients.
Endoscopy depicted gastric ischemia and ischemic col-
itis in one (patient 6) and five patients (patients 2, 8, 13,
15, and 17), respectively.
Angiographic findings and PPSR
Based upon DSA and CT findings, stenosis or occlu-
sion was situated within the proximal 3 cm of the
splanchnic artery. The etiology of the splanchnic sten-
osis/occlusion was most likely an atherosclerotic plaque
with or without thrombosis in each case.
In two (patients 9 and 17) and one (patient 15)
cases simultaneous stenting of the celiac trunk and
SMA as well as simultaneous stenting of the SMA
and IMA were carried out. In four of 22 arteries
(18%), two stents were inserted into one artery.
Median duration of PPSR was 80min (range, 20–
200min). In total, 21 of 22 arteries were successfully
revascularized resulting in a technical success rate of
95%.
One peri-interventional complication occurred: in
patient 12 it was attempted to revascularize an occlu-
sion of the celiac trunk via the left brachial access. The
patient was limited cooperative and angiographic image
quality was significantly reduced due to motion arti-
facts and obesity. After several attempts it was con-
sidered that the celiac trunk was successfully
catheterized and two stents were placed at the site of
the presumed stenosis. Control angiography showed
that the stents were erroneously implanted into
the SMA.
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Clinical course and follow-up
Post-interventionally, in 10 of 19 patients the symp-
toms of AMI resolved and/or serum lactate normalized
without need of further specific therapy, leading to a
clinical success rate of 53%.
Seven of the nine patients without clinical success
(78%) underwent subsequent laparotomy with bowel
resection in four patients after a median time interval
of 3.5 h (range, 1 h–18 days). One of these patients sur-
vived (patient 9).
The overall 30-day mortality was 42% (8 of 19
patients). The three patients with pneumatosis intesti-
nalis died. The 30-day mortality of patients with at
least one post-interventionally occluded splanchnic
artery was 75% (6 of 8 patients).
Eleven of 19 patients (58%) survived the 30-day
post-interventional period, including four of five
patients (80%) with a history of CMI, and were dis-
charged from hospital after a median stay of 4 days.
None of the surviving patients exhibited short-bowel
syndrome during a median follow-up of 43 months
(range, 1–81 months).
Discussion
Unfortunately, mortality of patients with AMI remains
high (8,20,21,24) as diagnosis and therapy are often
delayed (8,25), the majority of patients presents with
several co-morbidities (1,5,21,26), and open revascular-
ization is still a major trauma – particularly in patients
with increased surgical risks (5,9–12).
Recent data show overall mortality rates of about 30–
50% for patients with AMI undergoing traditional open
surgery (20,21,27–29). Here, duration of acute symp-
toms of more than 24 h was associated with a further
increase of mortality to 70–80% (21,27,28). In compari-
son, in the present study the overall 30-daymortality was
lower (42%)with amedian time fromonset of symptoms
of 50 h.Also,Arthurs et al. reported prolonged symptom
duration for patients treated by an endovascular
approach (62 h) with significantly lower mortality when
compared to open surgery (20).
We believe that not only duration of symptoms and
the choice of treatment, but also other factors such as
the rate of residual bowel perfusion, due to incomplete
vessel occlusion or capable collateral circulation, have
additional influence on overall outcome (13,14). This is
supported by the observation that most of our patients
with a history of CMI survived the post-interventional
period (4 out of 5 patients).
The impact of co-morbidities was further docu-
mented by Marchena-Gomez et al. (26) who analyzed
patients with AMI undergoing open surgery. In their
study, the perioperative mortality of patients with a
CCIa score of greater than 4 was 72% (26). In the
present study, the majority of patients (89%) exhibited
a CCIa score of greater than 4 and the 30-day mortality
was as low as 42%. Hence, patients with severe co-
morbidities might particularly benefit from PPSR.
Other endovascular studies reported mortality rates
below 30% (1,14,21). However, only few data exist
on PPSR only in atherosclerotic AMI, and several of
our patients were considered inoperable. Thus, the clin-
ical outcome of our study population is clearly in keep-
ing with what has been observed by other authors.
Although we favor the endovascular approach as
described in this report, the following drawbacks of
PPSR have to be taken into account carefully: (i)
PPSR might delay resection of necrotic bowel. A
hybrid surgical room with facilities for both percutan-
eous and open surgical intervention can save valuable
time (13). This technique was not used in our center for
the here reported group. (ii) Percutaneous revasculariza-
tion of (chronically) occluded arteries can be technically
challenging. In our study population eight patients had
at least one chronic splanchnic occlusion, none of these
vessels were revascularized percutaneously and 30-day
mortality was high for this subgroup of patients
(75%). Surgical revascularization of occluded arteries
might have improved outcome (1,4). (iii) Pneumatosis
intestinalis indicates advanced AMI and is usually asso-
ciated with transmural bowel necrosis (30). In the pre-
sent study three patients with pneumatosis intestinalis
underwent PPSR. All three patients died. In another
study two patients with pneumatosis intestinalis also
received primary percutaneous treatment and died
(17). Therefore, we currently believe that immediate
laparotomy is indicated for patients with pneumatosis
intestinalis. (iv) Three of eight patients dying within
30 days (38%) suffered from cardiac complications. In
these three patients, inflammatory molecules of the
bowel possibly entered circulation and induced ische-
mia-reperfusion injury (13). Hence, cardiac complica-
tions must be carefully avoided when possible.
We believe that our current retrospective study can
contribute to hypothesis generation in the field of intes-
tinal reperfusion by the endovascular route. However,
the following limitations must be taken into account: (i)
there is a potential selection bias towards patients with
a higher rate of co-morbidities, increased surgical risks,
and in whom PPSR of at least one splanchnic artery
was considered possible; (ii) data of time to interven-
tion, balloon dilatation prior to stent placement,
administration of acetylsalicylic acid during interven-
tion as well as duration of clopidogrel administration
post-intervention could not be fully obtained due to the
retrospective nature of the study; and (iii) the study
population is clearly limited in number due to the nov-
elty of the approach. Further prospective trials with
larger sample sizes are needed.
In conclusion, in our study population of 19 selected
patients with atherosclerotic AMI presenting with severe
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co-morbidities (CCIa>4 in 89%), prolonged acute symp-
toms (median, 50h) as well as significant surgical risks,
PPSR of splanchnic stenoses was technically feasible.
Clinical outcome was acceptable overall (30-day survival
58%), although splanchnic occlusions and signs of bowel
necrosis were associated with worse outcome.
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Supplementary material is available online at acr.sagepub.
com/supplemental.
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